Justin A. Renz - 18 Mar 2026 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: CFO
Issuer ticker: ZVRA
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Mar 2026, 16:15:55 UTC
Prior SEC filing: 25 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian Keane, Attorney-in-Fact for Justin Renz

Key filing fact

Justin A. Renz filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 19 Mar 2026.

Key facts

This page summarizes Justin A. Renz's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Mar 2026, 16:15.

Change

Previous filing in this sequence was filed on 25 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001466562 Primary reporting owner

Renz Justin A

Relationship: CFO
Address: C/O ZEVRA THERAPEUTICS, INC., 101 FEDERAL STREET, BOSTON
Signature: /s/ Brian Keane, Attorney-in-Fact for Justin Renz
Signature date: 19 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +300,000
Change %
Price: $0.000000^*
Shares after: 300,000
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $9.55
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026.

Footnote F2

Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.